We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Venn Life Sciences Holdings Plc | VENN | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 6.85 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 6.85 | 6.85 |
| Top Posts |
|---|
Posted at 21/6/2019 12:07 by yump Apparently VENN was 'under-capitalised'.That's why their revenue dropped, although there isn't any explanation of exactly how that process worked. No quotes of 'this that and the other potential client wouldn't give us the contract because our balance sheet looked rubbish'. Believe that and you'll believe anything. 'Orphan drugs': the ones nobody will touch because they require government or other subsidy (new shareholders ??) to make them commercially viable. |
Posted at 13/6/2019 20:37 by aishah Venn Life Sciences – shares restored at a massive premium… but much more to come |
Posted at 13/6/2019 20:31 by jpuff So what's the verdict on the corporate action? (Given I'm an existing long suffering holder of Venn)? |
Posted at 11/6/2019 08:19 by cocker I agree and although it has served me well Buywell I still am not 100% convinced that the constant dilutions are in the interest of shareholders. I sold my remaining few shares of 35k in Venn 1st thing as TU wasn't impressive |
Posted at 10/5/2019 07:45 by jpuff AIM Suspension - Venn Life Sciences Holdings PlcSource: UK Regulatory (RNS & others)TIDMVENNRNS Number : 5713YAIM10 May 2019NOTICE10/05/2019 7:30amTEMPORARY SUSPENSION OF TRADING ON AIMVENN LIFE SCIENCES HOLDINGS PLCAt the request of the Company trading on AIM for the under-mentioned securities has been temporarily suspended from 10/05/2019 7:30am, pending publication of an admission document and an announcement.ORDINAR |
Posted at 01/5/2019 11:28 by cocker Venn life has just dumped 630k worth of Skin shares |
Posted at 11/12/2018 11:59 by rivaldo For the record from the analyst at Davy this morning...."DAVY VIEW Venn’s strategic collaboration with Open Orphan should feed through into new business opportunities in the high growth orphan (rare) disease market – an area of strong focus for Venn. The principles of Open Orphan will be joining Venn’s Board – Professor Brendan Buckley was previously Chief Medical Officer for ICON and brings a wealth of experience and a business network that should benefit Venn. The new financing consisting of £1m loan notes means more capital is available for Venn to invest in the business and possible M&A. Our FY 2018 and FY 2019 revenue forecasts are now €13.8m and €16.5m respectively. Our FY 2018 and FY 2019 EBITDA forecasts are -€0.5m and €0.4m respectively." |
Posted at 20/10/2016 17:54 by glasshalfull You may be interested in the further developments of the Integumen spin off vehicle which is acquiring Enhnace Skin Products - VISIBLE YOUTH brand - for £3m which will translate into a 24% shareholding in Integumen alongside Venn's 30%.Enhance Skin Products Inc. Announces a Strategic Collaboration With Integumen Limited and Asset Sale Enhance Skin Products Inc., a pioneer in hyaluronan ("HA") research and development for deep hydration of the skin, announces that it has entered into a conditional Asset Purchase Agreement ("APA") with Integumen Limited ("Integumen") under which it will sell substantially all of the Company's assets under a plan of reorganization. The consideration payable under the APA is a sum equal to £3,030,000 ($3,939,000), subject to adjustment depending on the level of Enhance' s current liabilities as at completion. The consideration is comprised of £2,715,000 ($3,529,500 ), subject to any adjustment under the APA and less all sums due and owing under the note owing from the Company to Integumen, to be settled by the allotment of ordinary shares of Integumen at a price of £1 per share at par credited as fully paid, and the assumption of certain liabilities of the Company up to the value of £315,000 ($409,500). The APA is subject to shareholder approval and the company complying with all applicable state and federal law related to such sale. On October 4, 2016 Venn Life Sciences ( AIM : VENN ), a United Kingdom Contract Research Organisation providing drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announced that its wholly owned subsidiary, Venn Life Sciences Limited, has entered into a conditional agreement with Integumen under which it and Lynchwood Nominees Limited, as custodian for the Helium Rising Stars Fund would sell the entire issued share capital of Innovenn UK Limited ("Innovenn"), for a total consideration of up to £4.7 million. The consideration for Innovenn has been agreed at £4,740,000, subject to adjustment depending on the level of Innovenn's current liabilities as at completion. Part of the consideration for the Sale will be settled by the assumption by Integumen of £146,032 of Innovenn's debt, with the balance of £4,593,968 being settled by the allotment of ordinary shares of £1.00 each in the capital of Integumen at par credited as fully paid. The Innovenn sale is subject to the approval of the shareholders of Venn Innovenn was founded by Venn in 2014 as an innovation vehicle dedicated to the development and marketing of healthcare products and technologies. Innovenn acquired Labskin, a living skin model, and an anti-acne formulation and since acquisition has invested in the further development and commercialisation of these assets. Integumen Limited was established on May 28, 2016 for the purpose of building a business in the area of Human Surface Science. Integumen plans to acquire the business of Innovenn, Enhance and complementary businesses in the areas of Skin Science, Oral-health and Wound-care. The acquisition of Innovenn and other businesses is to be completed by way of the issue of new shares in Integumen. Integumen plans to seek admission of its shares to trading on AIM and plans to raise capital to fund the future development and commercialisation of the technology portfolio. Integumen has appointed advisors in this regard. Prior to a potential listing and fundraise Integumen will fund its activities out of existing cash reserves and a bank loan facility for EUR 1m which Venn currently guarantees. In addition to the acquisition of Innovenn, Integumen is in the process of acquiring three additional businesses. The first of these transactions is the acquisition of the Enhance business. In addition to Innovenn and the Enhance asset purchase, Integumen has agreed terms to acquire a European based Oralhealth company. The purchase is to be by way of a purchase of shares and Integumen is targeting the completion of this transaction in the coming weeks. The target currently has an oral hygiene product in the market place with international distribution. Finally, Integumen intends to complete the acquisition of a woundcare business with products in development in the areas of wound diagnostics and infection control. This acquisition is to be completed by way of a purchase of shares and Integumen expects to complete this transaction in the coming days. On completion of the aforementioned transactions, Integumen would have a portfolio of intellectual property and products across four complementary healthcare sectors. On completion of all four transactions Venn and Enhance would own approximately 30% and 24%, respectively, of the equity of the combined businesses, subject to any adjustments under the APA. Although the Board understands that Integumen intends to enter into the above transactions there is no guarantee that all or any of these will be completed. The UK Pound Sterling (£) amounts have been converted into US dollars at the closing US$/£ sterling interbank spot rate on September 30, 2016 of 1.3 for the convenience of readers. Donald Nicholson, Enhance's President & CEO stated that " we are delighted to have entered into this strategic collaboration with Integumen Limited. The combined businesses should benefit from: diversified risk; existing sales of products and services; "cross-franchise" opportunities to incorporate patented technologies into new products; access to a wider range of core skills (including marketing, development and formulation) and critical mass for enhanced access to capital." Declan Service, Integumen's CEO stated " we see Enhance's Visible Youth™ assets as a key component of the Integumen Group. The consolidation of branded products at different stages of commercialization, within a niche range of commercial markets should enable the combined group to build a sustainable business focused on the consumer and professional OTC healthcare markets". Visible Youth™ The Visible Youth ™ consumer and professional skincare lines are based on a patented synergistic combination of Hyaluronic Acid and bioactive glass micro particles created by one of the world's leading authority in hyaluronic technologies. The brand has a pharmaceutical, research driven heritage based on over 30 years of pioneering research. The Visible Youth™ skin care lines only utilize high purity, medical-grade HA of a specific combination of grade, purity and molecular size to provide optimum hydration and targeted dermal delivery. HA is a known anti-oxidant with moisturising, anti-wrinkle and dermal delivery properties. Bioactive glass micro particles have established strong anti-oxidant, anti-redness, anti-wrinkle, mineral enhancement properties and have strong anti-inflammatory activity. The patented HA Bioglass combination is unique to Enhance. The Visible Youth formulations also include additional naturally derived ingredients specific to each skin care need. Intellectual Property Base patents for a stable cosmetic composition of HA and bioactive glass have been granted to Enhance in the USA, Australia, New Zealand, China and Japan. We are in final stages of patent prosecution in the European Union and Canada. The Company has also filed an International patent application for the use of HA and bioactive glass to enhance and extend the anti-wrinkle effects of cosmetic treatments associated with aesthetic injectables such as Botox (botulinum toxin) and cosmetic dermal fillers. The Visible Youth Trademark has been granted in USA, EU, Canada, France, Japan & Switzerland. A trademark application is currently in process in China. --- Kind regards, GHF |
Posted at 05/10/2016 09:20 by aishah Beaufort View:Venn Life Sciences (VENN.L, 23.75p) - Speculative Buy Venn Life Sciences (Venn) informed that its wholly owned subsidiary, Venn Life Sciences Limited, has entered into a conditional agreement under which it and Lynchwood Nominees Limited, as custodian for the Helium Rising Stars Fund, would sell the entire issued share capital of Innovenn UK Limited (Innovenn) for a total consideration of up to £4,740,000. The consideration amount would be settled by the assumption by Integumen of £146,032 of Innovenn's debt, and the balance of £4,593,968 being settled by the allotment of ordinary shares of £1.00 each in the capital of Integumen at par credited as fully paid. Venn founded Innovenn in 2014 as an innovation vehicle dedicated to the development and marketing of healthcare products and technologies. Prior to the sale, the subsidiary converted its loan to Innovenn of £1,294,491 into ordinary shares of £0.001 each of Innovenn, increasing its shareholding to 70% of the issued share capital of Innovenn. The other shareholder of Innovenn is the Helium Rising Stars Fund, a Cayman-domiciled fund that invests in small UK companies. Our view: The sale of Innovenn is positive news for Venn. Innovenn has made good progress in moving from its development phase into commercialisation. The transaction would allow performance of Venn's core CRO business to be more visible. Venn reported solid performance in H1 2016 and made good progress on both operational and financial fronts. Venn reported a sharp jump in revenue and improved EBITDA for H1 2016. Strong Cash reserves should help the Company deliver on its growth plans. Venn made progress on the integration of Kinesis and achieved initial cross sales. The Company expects to benefit from the acquisition of Kinesis in H2 2016. Venn extended its operating capabilities into the USA with the establishment of Venn Inc and the appointment of a VP of Operations USA. The Company has a solid line of opportunities for H2 2016 and remains fundamentally strong. Therefore, we retain a Speculative Buy rating on the stock. |
Posted at 30/9/2016 00:27 by timbo003 There were approximately 20 attendees at the meeting last night which included around 10-12 private investors, Tony Richardson (Venn CEO), Jonathan Hartshorn (Venn CFO), Anna and Leanne from Walbrook and a few folk from some city brokers (Shard, Beaufort and possibly others). The Walbrook events at the Rocket Bar tend to be fairly informal with lots of questions asked during the presentations which is a good format given that the venue is a licenced bar.TR’s presentation was basically an overview of the company’s origins, its current business and its future strategy. As is often the case, it was the Q&As that helped reveal the most interesting nuggets, the majority of which I have detailed below (in no particular order): The Innovenn division is currently loss making, when the Innovenn technology was acquired from Evocutis plc in 2014 (for £210k) it was hoped that it might add value to the business and hence to the share price, this has not occurred so the decision has been taken to divest this part of the business. Venn have investigated a number of disposal routes and they are now actively pursuing one of these options (a spin out). If all goes according to plan it sounds like we may hear something in the next couple of months or so and shareholders would own shares in the new spin out. The two analysts that currently cover Venn attribute zero value to Innovenn. Should the spin out go ahead a value would be attributable to the spin out shares and Venn would be free from a loss making division, this should have a positive effect on profits and hopefully have a knock on effect on the share price. Venn’s biggest clients are largish US biotechs who wish to conduct small to medium size clinicals in Europe. Venn do have Big Pharma clients but they tend to use Venn for small discrete programs of work. Big Pharma tend to select big CROs for their large phase III studies as they are the only ones with the scale and capabilities. There are no immediate plans to expand geographically outside of Europe, although Venn may consider one or more small bolt on acquisitions for Eastern Europe where they are under-represented. Some US based clients have indicated that it would be useful if Venn had some US presence, so they may acquire a small business in the US or increase headcount modestly to give themselves some local US capabilities. Small acquisitions may not ncessarily be funded through the issue of equity and may be financed with debt. In response to a question on future placings, TR did say that if there were to be another equity raise, they would look at ways to include an open offer with any institutional placing. Venn do not have a dedicated phase I unit (which would require considerable Cap-Ex) and they do not have capabilities to conduct large multi country Phase III studies for large Pharma, so they will stick to what they do best, i.e. small phase II and phase III studies. In response to a question on how are PIs supposed to know what market expectations were for the company, we were told that Venn were currently covered by two different brokers and that they do not intend to commission paid for research from service providers such as Hardman or Equity Development. If shareholders gave TR/JH their contact details they would ensure that they were on the distribution lists for research updates. The last acquisition was Kinesis, this was a complementary business as Kinesis was focused on early stage clinical development activities, whereas the existing Venn business was later stage, since the acquisition there was been considerable cross selling of services between the two businesses. There were some staff losses following the Kinesis acquisition, but this is often the case when a privately held CRO is acquired, some staff feel a loyalty to the old owner and do not feel comfortable moving across. The rates charged to clients for contracts on a time and materials basis are between 80Eur/hr /person and 250 Eur/hour/person, with the rate depending on the level of expertise of the staff involved. The effect of Brexit has been fairly neutral so far, although we don’t know what will happen from a regulatory perspective and no one knows where EMA will be located (currently it’s in Canary Wharf). Ireland should be a winner as far as the Pharma industry is concerned (assuming Brexit goes ahead) as it will be the only remaining English speaking country in the EU. The current potential pipeline of projects is around 20m Euro, which is a lower figure if you risk adjust, although 50% of next year’s forecast revenue (forecast around £18m) is in the bag. If a Client puts a project out to tender they may typically approach 3 CROs. Venn’s current hit rate for tendered contracts is around 1 in every 2 (to 2.5) which is an improvement from a year or so ago when it was more like 1 in every 3. After the official close of the meeting it was a free bar and canapes so like most other attendees, I was in no rush to leave so opted to hang around for another hour or so just shooting the breeze. (Please feel free to copy or plagiarise on iii, LSE or wherever) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
